2
Record financing rounds at the Munich biotech hub
Ein Dokument
mehr
Ergebnis der Suchanfrage nach Ingelheim
Inhalte
- Kategorie:
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
72 Treffer
Technische Universität München
Start-up dedicated to developing new antibiotics
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Smartbax nominated for Falling Walls award Start-up dedicated to developing new antibiotics • New approach against resistant pathogens • Agent damages protein transport and energy balance of bacteria • Two TUM spin-offs nominated for Science Breakthrough of the Year at Falling Walls Summit It all began with basic research: While conducting laboratory experiments, a team ...
mehrBerlin Global Advisors enters new practice areas and sectors with former Thyssenkrupp board member
Berlin (ots) - - Dr. Donatus Kaufmann, long-standing board member of Thyssenkrupp, joins the management team of Berlin Global Advisors (BGA) as Senior Partner as of February 3, 2021 - With Donatus Kaufmann, the renowned business and political consulting firm enters promising sectors such as strategic transformation, M&A and IPO advice as well as innovation management & ...
mehrEvoBiotiX collaborates with Boehringer Ingelheim and the University of Salzburg on naturally derived Extracellular Vesicles (EVs)
Salzburg/Melide(CH) (ots) - Swiss Biotech EvoBiotiX SA today announced a multi-year collaboration with Boehringer Ingelheim in the field of naturally derived EVs. A significant part of this program will fund research of the drug delivery potential of naturally derived EVs in the group of Prof. Meisner-Kober at the ...
mehrTechnische Universität München
From cancer medication to antibiotic: modified cancer drug effective against multi-resistant bacteria
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35822/ High resolution images: https://mediatum.ub.tum.de/1524870 NEWS RELEASE From cancer medication ...
mehrHigh investor density at the Pitch Day hosted by IZB
Ein DokumentmehrBoehringer Ingelheim's afatinib Achieves Primary Endpoint in Global Phase III Study in Recurrent/Metastatic Head and Neck Squamous Cell Cancer
Ingelheim, Germany (ots/PRNewswire) - - Results from the LUX-Head & Neck 1 study show afatinib* significantly delayed tumour growth versus chemotherapy in patients following failure of their previous treatment, reducing the risk for disease progression by 20% - Head and neck cancer has a very poor prognosis with no ...
mehrBoehringer Ingelheim Initiates First Phase III Clinical Trial in Ovarian Cancer
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME-Ovar-1 trial, investigates the compound BIBF 1120, a novel oral anti-angiogenic agent[1], ...
mehrFlibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Ingelheim, Germany, November 16 (ots/PRNewswire) - - Results Support Flibanserin as a Potential Treatment for HSDD, an Under-Recognised Women's Sexual Health Condition - For Medical Media, Outside the US Only Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg taken once daily at ...
mehrBoehringer Ingelheim Receives Approval From the European Commission for Mirapexin(R)/Sifrol(R) Prolonged-Release, Once Daily Tablet for the Treatment of Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - New Formulation Brings the Established Efficacy of Mirapexin(R)/Sifrol(R) to Patients With Parkinson's Disease in the Convenience of a Once Daily Dose Boehringer Ingelheim today announced that the Mirapexin(R)/Sifrol(R) (pramipexole) new prolonged-release , once daily tablet ...
mehrBoehringer Ingelheim's Diabetes Pipeline Continues to Advance as the Company Announces Conclusion of Robust Phase III Pivotal Trials Programme for linagliptin
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Media Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials. The company confirmed that first results from the Phase III clinical ...
mehrBoehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 (Tovok(TM)) as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Mutations
Ingelheim, Germany (ots/PRNewswire) - - Data From Phase II Studies Investigating BIBW 2992 (Tovok(TM)) and BIBF 1120 (Vargatef(TM)) in NSCLC Patients Presented at 13th World Conference on Lung Cancer (WCLC) INGELHEIM, Germany, August 3 /PRNewswire/ -- Boehringer Ingelheim announced today at the International ...
mehrHead-to-Head Trial Demonstrates Viramune(R)'s Similar Efficacy and Superior Effect on Lipid Profile Compared to atazanavir/ritonavir
Cape Town, South Africa (ots/PRNewswire) - - For Medical Media Outside the US Only Results from the ARTEN* trial presented at the 5th International AIDS Society (IAS) conference in Cape Town, South Africa demonstrated non-inferiority regarding efficacy between Viramune(R) (nevirapine) and ritonavir boosted ...
mehrEuropean Commission Approves Statement on Lipid Improvement for VIRAMUNE(R) Label
Ingelheim, Germany (ots/PRNewswire) - - For Medical Media Outside the US only Boehringer Ingelheim announced today that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) for VIRAMUNE(R) (nevirapine) in the treatment of patients with HIV. The decision followed a positive recommendation by the Committee for Medical Products ...
mehrBoehringer Ingelheim Receives Positive Recommendation From European Scientific Committee for a New Once Daily Mirapexin(R) (Pramipexole) Formulation for the Treatment Of Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - For non-U.S. Healthcare Media Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending the approval of a once daily formulation for Mirapexin(R) / ...
mehrNew Data From Boehringer Ingelheim's Ongoing Linagliptin Trial Programme Show Promising Safety and Efficacy Results
Ingelheim, Germany (ots/PRNewswire) - - Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the scientific sessions of this year's American Diabetes Association Annual ...
mehrBoehringer Ingelheim and the World Stroke Organization Announce Partnership in the World Stroke Academy
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A., Canada, and Japan Boehringer Ingelheim announced today that it will become the founding sponsor of the World Stroke Academy, a novel training initiative for stroke professionals being developed by the World Stroke Organization (WSO). ...
mehrOutcome of New Mirapexin(R)/Sifrol(R) (Pramipexole) Study set to Change Treatment of Depressive Symptoms in Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - New Study Shows That Mirapexin(R)/Sifrol(R) (Pramipexole) Relieves Depressive Symptoms of Parkinson's Disease (PD), a Common Non-Motor Symptom Affecting PD Patients' Quality of Life - For Non-US Healthcare Media To view the Multimedia News Release, go to: ...
mehrNew Study Results Support Once Daily, Prolonged Release Formulation of Mirapexin(R)/Sifrol(R) (Pramipexole) for the Treatment of Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - Data for the Once Daily Mirapexin(R)/Sifrol(R) (Pramipexole) Formulation Under Development Show Efficacy, Safety and Tolerability Outcomes Comparable to the Current Immediate Release Formulation for the Treatment of Parkinson's Disease For non-US Healthcare Media First data ...
mehrNo Increased Risk of Treatment-Induced Augmentation in Restless Legs Syndrome (RLS) Demonstrated in Long-Term Placebo-Controlled Study With Mirapexin(R) / Sifrol(R) (Pramipexole)
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media outside the U.S.A. New data presented today at the 61st Annual Meeting of the American Academy of Neurology (AAN), in Seattle, U.S.A. show that augmentation did not significantly differ in RLS patients treated with Mirapexin(R) /Sifrol(R) (pramipexole*) ...
mehrExperts Unite to Create New Online Resource for Restless Legs Syndrome
Ingelheim, Germany (ots/PRNewswire) - - Unique Educational Website 'Under the Covers of Restless Legs Syndrome (RLS)' is Launched on World Sleep Day - For Non-US Healthcare Media The website http://www.rlsunderthecovers.com brings together leading medical experts in the field of Restless Legs Syndrome (RLS) who have undertaken to explain key facts and symptoms of this ...
mehrECASS 3 Study Receives Recognition From the European Stroke Organisation and The Lancet
Ingelheim, Germany (ots/PRNewswire) - - ESO Recommends Extended Time Window for Actilyse(R) INGELHEIM, Germany, January 30 /PRNewswire/ -- - For Healthcare Media outside the U.S.A., Canada, and Japan Based on key results from the European Cooperative Acute Stroke Study (ECASS 3), the European Stroke Organisation (ESO) now recommends that Actilyse(R) (alteplase) be ...
mehrFirst Pivotal Trials Begin for Boehringer Ingelheim's Novel Triple Angiokinase Inhibitor Vargatef(TM) (BIBF 1120)
Ingelheim, Germany, November 17 (ots/PRNewswire) - - Progress Continues Across Expanding Oncology Pipeline With Two Compounds now in Phase III Clinical Development and a Potential First-in-Class Polo-Like Kinase 1 Inhibitor Soon to Enter Phase II - For non-US Healthcare Media Boehringer Ingelheim has marked a new ...
mehrPersonalising Cancer Care - An Invitation
Ingelheim, Germany, November 5 (ots/PRNewswire) - - For Non-US Healthcare Media Can the quest for personalised medicine in cancer therapy ever be realised? And how far have we come in the journey to personalised cancer care? What lies ahead from a clinical research perspective will be discussed in an international media webcast entitled "Probable or pipedream: could new cancer targets change the outlook for personalised ...
mehrLargest Study of its Kind Reveals Low Sexual Desire is Most Common Female Sexual Problem
Ingelheim, Germany (ots/PRNewswire) - - 1 in 10 Women Experience Distress Associated With the Most Common Form of Female Sexual Dysfunction, yet the Condition Remains Largely Under-Recognised and Under-Diagnosed - For non-US media only Results from the PRESIDE*(1) survey, the largest study assessing the prevalence of female sexual problems, show that low sexual desire ...
mehrTelmisartan (MICARDIS(R)) as Effective as Ramipril But With Better Long-Term Tolerability in High-Risk Cardiovascular Asian Patients
Beijing (ots/PRNewswire) - New results from the landmark ONTARGET(R) Trial show that, in Asian patients at high risk of cardiovascular disease (CVD), telmisartan (MICARDIS(R)) 80mg is as effective as, and significantly better tolerated than, ramipril 10mg in reducing the risk of cardiovascular death, heart attack, ...
mehrBoehringer Ingelheim Broadens Oncology Pipeline With Promising New Data for Potentially First in Class Plk1 Inhibitor
Ingelheim, Germany (ots/PRNewswire) - - BI 6727, a Highly Potent and Selective Plk1 inhibitor, Represents Latest Advance in Company's Plk1 Programme - For non-US Healthcare Media Boehringer Ingelheim's most promising new cell cycle kinase inhibitor and potentially first-in-class compound, BI 6727, has shown ...
mehrFrom Curiosity to Discovery: Boehringer Ingelheim's Pipeline Update Unveils Novel Investigational Compounds Heralding the Company's Entry Into Type 2 Diabetes
Ingelheim and Biberach, Germany (ots/PRNewswire) - - Boehringer Ingelheim Oncology Pipeline Advances: Two Leading Compounds are Entering Phase III Trials - Boehringer Ingelheim's Investigational Compound in Development for the Treatment of Pre-Menopausal Women Suffering From Hypoactive Sexual Desire Disorder (HSDD) ...
mehrRecent Research Shows Significant Benefits in Acute Ischaemic Stroke With Actilyse(R) Beyond Currently Approved Three Hour Treatment Window
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A., Canada, and Japan - Favourable Safety and Efficacy Profile of Actilyse(R) Confirmed by ECASS 3 Study Investigating Treatment in an Extended Time Window up to 4.5 Hours After Symptom Onset First results from ECASS 3 (European Cooperative ...
mehrFirst Landmark ARB Trial Against Placebo Shows MICARDIS(R) (Telmisartan) Reduces the Risk of Cardiovascular Death, Heart Attack and Stroke in ACE-Intolerant High-Risk Patients(1)
Munich, Germany (ots/PRNewswire) - - TRANSCEND(R), Parallel Trial to ONTARGET(R), Confirms Long-Term Protective Benefits and Excellent Tolerability Profile of Telmisartan 80mg(1) on Top of Current Best Standard of Care MUNICH, Germany, August 31 /PRNewswire/ -- - For non-US Healthcare Media The results of the ...
mehr
123Nächste